Venezuela (Bolivarian Republic of)

Population 2018 29 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>14 (11–17)</td>
<td>48 (37–60)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>1.2 (0.41–2.5)</td>
<td>4.2 (1.4–8.6)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.4 (0.15–0.77)</td>
<td>1.4 (0.52–2.7)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>0.73 (0.69–0.78)</td>
<td>2.5 (2.4–2.7)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.27 (0.088–0.55)</td>
<td>0.94 (0.3–1.9)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status
- % pulmonary
- % bacteriologically confirmed*ºº
- % children aged 0-14 years
- % women
- % men

Total new and relapse 11 017

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status
- % pulmonary
- % bacteriologically confirmed*ºº
- % children aged 0-14 years
- % women
- % men

TB case notifications, 2018

Total new and relapse 11 017

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status
- % pulmonary
- % bacteriologically confirmed*ºº
- % children aged 0-14 years
- % women
- % men

Patients with known HIV status who are HIV-positive 473 7%

- on antiretroviral therapy 300 63%

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistanceººº
  - New cases 6%
  - Previously treated cases 44%

Laboratory-confirmed cases* MDR/RR-TB: 43, XDR-TB: 0

Patients started on treatment* ** MDR/RR-TB: 41, XDR-TB: 0

MDR/RR-TB cases tested for resistance to second-line drugs 37

Treatment success rate and cohort size

| New and relapse cases registered in 2017 | 82% | 10 647 |
| Previously treated cases, excluding relapse, registered in 2017 | 74% | 305 |
| HIV-positive TB cases registered in 2017 | 88% | 528 |
| MDR/RR-TB cases started on second-line treatment in 2016 | 72% | 57 |
| XDR-TB cases started on second-line treatment in 2016 | 0 |

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment 2%
- % of children (aged < 5) household contacts of bacteriologically-confirmed 96% (71–100)

TB cases on preventive treatment

TB financing, 2019

National TB budget (US$ millions) 2.7

Funding source: 21% domestic, 0% international, 79% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR burden are produced by WHO in consultation with countries.
Generated: 2019-10-27